Beam Therapeutics (BEAM) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Novavax (NVAX) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 21.7% versus a loss of 1.4%. Over five years, BEAM leads with a -73.4% price change compared with -93.1% for NVAX. Beam Therapeutics is the larger company by market cap ($2.56 billion vs $1.85 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | NVAX |
|---|---|---|
| Share price | $24.77 | $11.22 |
| Market cap | $2.56B | $1.85B |
| 1-day change | -1.82% | -0.88% |
| YTD return | -10.64% | +66.96% |
| 1-year return | -1.43% | +21.69% |
| 5-year return | -73.41% | -93.07% |
| EPS (TTM) | $-0.68 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.26 | $13.39 |
| 52-week low | $20.23 | $6.20 |
| Distance from 52-week high | -35.26% | -16.21% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +110.54% | +24.78% |
| Average volume | 1.94M | 5.09M |
| Shares outstanding | 103.29M | 164.95M |
| Employees | 540 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed BEAM by 23.1 percentage points over the past year.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
BEAM vs NVAX FAQ
Which is bigger, Beam Therapeutics or Novavax?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.56B compared with $1.85B for Novavax (NVAX).
Which stock has performed better over the past year, BEAM or NVAX?
NVAX returned +21.69% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.